Rectal Cancer
AndroMETa-CRC-560: An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer (M24-560)
- Details
ClinicalTrials.gov ID:
NCT07525206
Diagnosis Type:
NA
USOR Number:
- Address
,
P: